Hepatitis C: How a Chronic Infection Became Curable

Hepatitis C is now one of the few chronic viral infections a clinician can genuinely cure. A short course of oral pills, taken for 8 to 12 weeks, clears the virus in more than 95 percent of people who finish treatment, and the field has agreed on an exact, testable definition of what "cured" means. Because that definition has been shown to predict longer survival and less liver cancer, it did more than change treatment. It changed who gets tested, shifting the recommendation from a short list of higher-risk groups to nearly every adult.

Key points#

• Direct-acting antiviral pills cure hepatitis C in more than 95 percent of treated adults over an 8 to 12 week course.
• Cure has a precise name, sustained virologic response (SVR): no virus detectable in the blood 12 weeks after treatment ends (SVR12).
• SVR is durable. Late return of the original virus is rare, which is what separates a cure from a temporary drop.
• Studies link SVR to lower overall death, less liver cancer, and fewer transplants, so regulators accept it as proof a drug works.
• The USPSTF now recommends one-time screening for all adults aged 18 to 79.

Screening moved from "who is at risk" to "everyone"#

For decades, testing for hepatitis C followed risk. Clinicians asked about injection drug use, blood transfusions before 1992, and other risk factors, then tested the people who fit. The trouble was that many infections do not fit a tidy profile, and a virus that can smolder silently for 20 years or more leaves few clues to prompt the question.

In 2020 the U.S. Preventive Services Task Force gave hepatitis C screening a Grade B recommendation for all adults aged 18 to 79. Two forces drove the change. Risk-based testing was missing a large share of cases, and infection rates had been climbing among younger adults. With a safe, short, and usually curative treatment now available, the older math no longer held: finding a hidden infection early is worth far more when the fix is a few weeks of well-tolerated pills.

The testing itself is simple. The first test looks for antibodies to the virus. A positive antibody result means the immune system has met the virus at some point, but it does not confirm an active infection, because a minority of people clear hepatitis C on their own. A reflex HCV RNA test then settles the question by looking for the virus itself. For most adults this is a one-time check, with repeat testing when risk is ongoing and testing during each pregnancy.

What "cure" actually means#

The word "cure" carries weight, so hepatitis C treatment ties it to a measurement rather than a feeling. Cure is defined as sustained virologic response: no hepatitis C virus detectable in the blood at a set point after the course ends. Earlier trials checked at 24 weeks (SVR24). The current standard checks at 12 weeks (SVR12), because the two results agree almost perfectly and SVR12 gives the answer sooner.

What makes SVR a cure rather than a pause is durability. Once someone reaches SVR, the original virus almost never comes back. Long-term follow-up shows late relapse is rare, which is the sharp line between today's therapy and the older treatments that could lower the viral load for a while only to let it rebound. The virus is cleared, and it stays cleared.

That framing also explains how to read the "more than 95 percent" figure honestly. It describes the share of treated people whose virus is undetectable months after finishing, a measure of viral clearance. It is not a forecast about everything that follows in a person's life.

From a blood test to a survival benefit#

A cure endpoint is only useful if it tracks outcomes patients actually care about, and SVR earned that trust through evidence. A 2012 study in JAMA followed people with chronic hepatitis C and advanced liver scarring and found that those who reached SVR had substantially lower death from any cause than those who did not. That work came from the older interferon era, when cures were harder to achieve and treatment was rough to tolerate, which makes the size of the benefit striking. Broader analyses since have pointed the same way: reaching SVR is tied to large drops in liver-related death, in hepatocellular carcinoma (the most common primary liver cancer), and in the liver failure that leads to transplant.

Because SVR reliably predicts these hard outcomes, it works as a validated surrogate endpoint. A drug can be tested in a trial that reads out in months using SVR12, instead of a study that waits years to count deaths and cancers, and regulators can judge a new antiviral on that basis. The AASLD-IDSA hepatitis C guidance, kept current by the major U.S. liver and infectious-disease societies, describes modern therapy as safe, short, and curative for most people, with SVR12 rates at or above 95 percent across treatment-naive adults, people with compensated cirrhosis, and people also living with HIV.

Reading the number without overselling it#

Three points keep the headline figure in proportion.

First, cure rates are an average across populations. People starting treatment without cirrhosis tend to do better than those with advanced disease, so any single percentage smooths over that range rather than promising you a personal result.

Second, cure is not immunity. Clearing the virus does not train your body to block the next one, so a new infection remains possible with repeat contact. Being cured once does not put you out of reach.

Third, cure does not undo damage already done. In people who had cirrhosis before treatment, the risk of liver cancer falls after SVR but does not drop to zero, which is why guidelines still call for ongoing cancer surveillance even after a documented cure.

None of that dims what changed. A disease that once ran silently for decades and fed a large share of liver transplants is now, for most people who are found and treated, a finite problem with a defined end. What made both the cure and universal screening defensible was a single measurable endpoint, validated against survival, standing underneath them.